Location History:
- Yokohama, JP (2015)
- Wako, JP (2022)
Company Filing History:
2 out of 856 
1 out of 8 
1 out of 1,035 
Years Active: 2015-2022
Title: The Innovations of Takehisa Matsumoto: A Pioneer in Antibody Research
Introduction
Takehisa Matsumoto, an esteemed inventor based in Wako, Japan, has made significant contributions to the field of biotechnology through his innovative research. With a total of two patents to his name, Matsumoto's work primarily focuses on the development of monoclonal antibodies that have the potential to advance treatments in areas such as hepatitis C.
Latest Patents
Matsumoto's latest patents encompass groundbreaking discoveries in the molecular biology sphere. The first patent details an isolated monoclonal antibody against the human Transforming Growth Factor-β (TGF-β) Latency Associated Protein (LAP) degradate. This antibody is capable of recognizing an integrin binding site within the TGF-β LAP degradate, which may open new avenues for understanding and manipulating TGF-β signaling pathways.
His second patent relates to the inhibition of TGF-β receptor activation caused by hepatitis C virus (HCV). The patent identifies a HCV-derived NS3 protease that binds to the type I TGF-β receptor, leading to its activation. Matsumoto's work outlines a method for screening compounds that can inhibit this activation, thereby providing a potential therapeutic approach for diseases linked to hepatitis C.
Career Highlights
Throughout his career, Takehisa Matsumoto has gained invaluable experience working with reputable institutions, including Riken Corporation and The Jikei University. His academic and practical pursuits have solidified his expertise in monoclonal antibody research, enabling him to contribute to important advancements in medical science.
Collaborations
Matsumoto has collaborated with distinguished colleagues such as Soichi Kojima and Mitsuko Hara. These partnerships have fostered an environment of innovation, allowing for the exploration of complex scientific challenges and furthering the impact of their collective research efforts.
Conclusion
Takehisa Matsumoto's work exemplifies the essence of innovation in biotechnology. His patents not only showcase his technical prowess as an inventor but also highlight the potential for his discoveries to translate into significant clinical applications. As researchers continue to build upon his findings, Matsumoto's legacy in the realm of antibody development will undoubtedly inspire future breakthroughs.